Levinneen NSCLC 1. linja:
Faasi 3, n=643. Canakimumabi + pembrolitsumabi + kemoterapia vs. pembrolitsumabi + kemoterapia.

PFS 6.8 kk vs. 6.8 kk, OS 20.8 kk vs. 20.2 kk.

NSCLC liitännäishoito:
Faasi 3, n=1382. Canakimumabi vuoden ajan vs. plasebo, sisplatiini-kemoterapian jälkeen.

DFS 35 kk vs. 29.7 kk (HR 0.94;95%CI, 0.78-1.14, p=0.258)

https://ascopubs.org/doi/10.1200/JCO.23.00980 Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
https://ascopubs.org/doi/10.1200/JCO.23.00910 Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial